Clinical Trial Update: Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a PARP inhibitor for BRCA-positive advanced ovarian cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Neoplasm

Drugs mentioned

• PARP inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2015-01-26